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Abstract
In quite a few diseases, drug resistance due to target variability poses a serious problem in pharmacotherapy. This is
certainly true for HIV, and hence, it is often unknown which drug is best to use or to develop against an individual HIV strain.
In this work we applied ‘proteochemometric’ modeling of HIV Non-Nucleoside Reverse Transcriptase (NNRTI) inhibitors to
support preclinical development by predicting compound performance on multiple mutants in the lead selection stage.
Proteochemometric models are based on both small molecule and target properties and can thus capture multi-target
activity relationships simultaneously, the targets in this case being a set of 14 HIV Reverse Transcriptase (RT) mutants. We
validated our model by experimentally confirming model predictions for 317 untested compound – mutant pairs, with a
prediction error comparable with assay variability (RMSE 0.62). Furthermore, dependent on the similarity of a new mutant to
the training set, we could predict with high accuracy which compound will be most effective on a sequence with a
previously unknown genotype. Hence, our models allow the evaluation of compound performance on untested sequences
and the selection of the most promising leads for further preclinical research. The modeling concept is likely to be
applicable also to other target families with genetic variability like other viruses or bacteria, or with similar orthologs like
GPCRs.
Citation: van Westen GJP, Wegner JK, Geluykens P, Kwanten L, Vereycken I, et al. (2011) Which Compound to Select in Lead Optimization? Prospectively
Validated Proteochemometric Models Guide Preclinical Development. PLoS ONE 6(11): e27518. doi:10.1371/journal.pone.0027518
Editor: Mark Wainberg, McGill University AIDS Centre, Canada
Received July 21, 2011; Accepted October 18, 2011; Published November 23, 2011
Copyright:  2011 van Westen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: GJPvW is a PhD student funded by Tibotec whose role involved contributing to the experimental data, validation of the results, and providing scientific
input into the design of the study (such as the improvement of modeling methods). The performing of the data analysis, and the decision to publish was not
influenced in any way by the funders. The authors’ collaborators from Tibotec helped in the preparation of the manuscript, however, no situation occurred where
the academic partners of the team were not able to publish what was desired. AB and API received funding from Dutch Top Institute Pharma (TI Pharma), project
number D1-105, who had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: The Non-Nucleoside Reverse Transcriptase Inhibitiros
Etravirine and Rilpivirine are marketed drugs developed by Tibotec, one of the funders of the current study. GJPvW was funded by Tibotec BVBA and JKW, PG, LK,
IV, AP and HWTvV are employees of this company. There are no patents, products in development or marketed products to declare. This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: ab454@cam.ac.uk
Introduction
Genetic Information is readily available
Over the last decade extensive sequencing efforts have unraveled
the human genome and provide an insight into the extent of human
genetic variation [1,2]. On the one hand this provides possible new
drug targets that can lead to new drugs [3–5]; on the other hand it
shows clearly that natural genetic variation needs to be addressed by
some form of personalized medicine that works in a particular
patient [6]. An exhaustive, individual ‘‘pharmacogenomics’’
approach for a patient, taking the full genetic make-up of a human
into account, is unfortunately not feasible in the short term. This is
due to the cost of sequencing but even more so to insufficient
understanding of biological processes in humans [7]. However,
what is already feasible today for every patient is the full sequencing
of pathogens such as bacteria and viruses, as these contain a
significantly smaller genome with relatively established locations
and functions of drug targets. It is now possible through ‘Deep
Sequencing’ technologies, to identify dominant and subdominant
viral strains present in an individual patient, paving the way for the
development of HIV inhibitors with an optimal potency profile
made to target all relevant HIV variants [8,9].
What is required for the development of an optimal preclinical
candidate on the other hand is a knowledge base of the effect
mutations have on the binding of current inhibitors. When this
information is available it can be used to create a model that
allows the user to extrapolate between target sequence variants
and predict binding affinities of preclinical compounds on
previously untested viral target sequences. While similar models
have been trained on this data for clinical drugs, these models
have in common that they solely are trained on recognizing
patterns of the presence and absence of mutations, thus only
considering target information [10–15]. They do not take into
account structural information of the compound – target
interaction; hence they are not able to rationalize why an
inhibitor is active on one sequence but not on another. As a
result, the application to the discovery of preclinical candidates is
rather limited.
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In the current work we present one approach to remedy the
situation, by making use of the large amount of structural data
available on the binding of HIV Reverse Transcriptase (RT)
inhibitors to their targets. We will show using prospective
experimental validation on hundreds of data points that we can
indeed predict which compound is preferable with regard to
activity against particular mutants, compared to other com-
pounds. In particular, our aim was to predict activity of
compounds on previously untested genetic variants of the virus.
Given our in-depth understanding of the structural differences
between viral enzyme sequences we can incorporate this
knowledge to arrive at much improved extrapolation abilities,
which enables the design of new inhibitors with improved broad
activity profiles.
Extrapolating in Target Space
When learning from bioactivity data, and attempting to make
predictions for novel chemical structures, statistical and machine
learning techniques have a proven ability to ‘make sense’ of large
data sets under certain conditions (such as interpretable variables
used in the model) and to relate chemical structure to activity
against a protein target. Bioactivity models are generally based on
the ‘Molecular Similarity Principle’ stating that similar compounds
(individual compounds or with respect to the distribution of
chemistry in a given data set) possess similar properties, such as in
this case similar bioactivity [16–18]. Yet conventional bioactivity
models possess a severe limitation when considering sets of targets,
which may be members of a target family such as kinases or G
protein-coupled receptors (GPCRs), or as in the case presented
here, sequences of viral enzymes. Those models take into account
multiple molecules active on a single protein target, yet they
completely neglect our extensive knowledge on the similarities of
targets to each other. Hence, conventionally a single bioactivity
model is generated for every target – neglecting that not only
similar compounds show similar bioactivity, but reversely also that
similar targets bind similar compounds. In addition, this concept is
crucial for the chemogenomics paradigm that has been receiving
lots of attention recently [19,20]. In practice this means that even
if a particular ligand-protein target data point is unknown, we can
often extrapolate from neighboring activities in both ligand and
target space, and not only in ligand space as has previously been
done.
In this work we employed a modeling technique called
‘proteochemometric modeling’ (PCM) to model bioactivity data
on a set of 14 enzyme sequences. This technique was introduced
by Lapinsh, Wikberg et al. [21,22] and similar approaches have
since appeared [23]. These techniques have been recently
reviewed by the authors [24]. However, no large prospective
studies have been presented until today. As PCM uses both ligand
and target information, the hypothesis of our work was that PCM
would be able to extrapolate the activity of compounds
encountered in the training set to novel target sequences. The
extension of bioactivity modeling and its impact on preclinical
drug research, plus the extensive prospective experimental
validation performed, is the main contribution of the current
work to the bioactivity modeling field. In addition, applications of
PCM to novel target families including, but not limited to: Class A,
B and C GPCRs; Kinases; Voltage-gated ion channels and others,
can also be covered by this concept. The flexibility of the method
is of particular interest when taking current multi-target drug
paradigms into account [25,26].
Methods
Data set used to build the models
The data set employed comprises 451 compounds and 14 HIV
RT sequences and hence 6,314 possible compound – target
combinations. The set was generously provided by Tibotec BVBA.
For a total of 4,024 of these combinations an activity value in the
form of a pEC50 value was available for training the bioactivity
model. Compounds with a pEC50 value on a certain sequence
closer than 0.3 log units to the toxic concentration for that
compound (expressed as pCC50) were discarded (81 compound –
sequence pairs). Table 1 shows the point mutations present in the
13 mutated sequences as well as the wild type (HXB2 / IIIB
reference strain [27], sequence 1 in the table) and the average
pEC50 per sequence. A graphic representation of our data set is
shown in Figure 1; a histogram of the pEC50 values of all
compounds – sequence pairs is available in Figure S8. A sample
dataset, the final full model (in the form of a pipeline pilot
component), and a protocol to perform PCM are included in the
electronic Supporting information.
Compound and protein descriptors
All descriptors were calculated in the academic version of
PipelinePilot 6.1.5 [28]. Ligands were described by Scitegic
FCFP_6 circular fingerprints [29,30], which have previously been
shown to capture a large amount of information with respect to
compound bioactivity [31,32]. FCFP_6 descriptors provide
individual substructures and treat these as a feature of a
compound. These substructures have a maximal diameter of 6
bonds from a central atom. In the final model we can link these
substructures to a change in pEC50.
Sequences were encoded based on the binding site sequence in
which each amino acid was represented as a single unique feature.
The residues used to define the binding site are shown in Figure 2
(PDB Code 2ZD1, HIV RT bound to Rilpivirine [33], created
with Molsoft ICM version 3.6-h) and Table 1. The residues used
to define the binding site are shown in red and black, where the
black residues are the ones that were mutated only in sequence 7.
The features describing the binding site were obtained by hashing
an array of 58 physicochemical properties obtained from the
AAindex database [34]; the used indices can be found in Table S3.
Finally, both ligand and protein fingerprints were converted to a
fixed length array of features which were then used in the
modeling. The ligands were converted to a fixed length array of
155 features while the sequences were converted to a fixed length
array of 24 features using default Pipeline Pilot settings.
Machine learning
Models were constructed in the academic version of Pipeline
Pilot 6.1.5 [28] using the R-statistics package. Support vector
machines (SVM) as coded in the e1071 package were used for
model creation [35]. Parameters gamma and cost were tuned over
an exponential range and epsilon was set at 0.2 as this was the
given assay error. It has been shown that setting epsilon to the data
error is the optimal value for training [36]. The optimal model was
determined using 5-fold cross validation before proceeding to
experimental prospective validation of the model. The parameters
used for validation were RMSE and R0
2, although the regular R
2
was also determined it has been shown that R0
2 provides better
reliability [37,38]. R0
2, in contrast to R
2, takes into account that
the regression line of our model predictions should intersect with
the origin. In silico validation on trained models was done via
learning curves (see Figure S9).
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To assess the prospective capabilities of PCM we used our final
model, which was trained on the full data set, to predict the
activity of all compounds for which no pEC50 value was available.
In total 835 data points were subsequently experimentally
validated, 317 of these represented novel predictions and 518
were repeat experiments to establish reproducibility of the assay.
The 317 novel predictions included 130 compound – sequence
pairs that were predicted to differ 2 standard deviations from
either compound average (69 compound – sequence pairs), called
compound outliers, or sequence average (61 compound – sequence
pairs), called sequence outliers. Therefore we specifically tested the
ability of our model to extrapolate outside of the bioactivity space
of ‘typical’ compound – sequence pairs.
The techniques used as a benchmark were QSAR, kNN and
pEC50 scaling. Individual QSAR models were trained for all
sequences based on the same FCFP_6 compound descriptors as
the PCM model. The kNN models were created based on Jensen
et al. [39]. In total nine kNN models were created. Three models
were based on only compound data using 3, 10 or 20 neighbors,
three models on only target data using 3, 10 or 14 neighbors and
three models based on both compound and target data using 3, 10
or 20 neighbors. In addition we also performed simple
interpolation of pEC50 values (‘scaling’), by assuming that the
affinity of a compound on a sequence follows the general trend
displayed by a series of other compounds. Thus, if a series of
compounds on average has a 0.3 log unit lower pEC50 value than
on the wild-type sequence, then the new compound is also
assigned a 0.3 log unit lower pEC50 value.
Antiviral assays
The antiviral activity of different inhibitors was determined in a
cell-based HIV-1 replication assay. Here MT4 cells (150,000 cells/
ml), stably transformed with an LTR-EGFP reporter gene, were
infected with HIV-1 (IIIB, clinical isolates, or site-directed
sequence strains; multiplicity of infection MOI=0.0025) in the
presence or absence of different inhibitor concentrations. After
three days of incubation, the amount of HIV replication was
quantified by measuring the EGFP fluorescence, and expressed as
EC50 values. The toxicity of inhibitors was determined in parallel
on mock-infected MT4 (150,000 cells/ml) cells stably transformed
with a CMV-EGFP reporter gene and cultured in the presence or
absence of test compound concentrations. After three days of
incubation, cell proliferation was quantified by measuring the
EGFP fluorescence, and expressed as CC50 values (cytotoxicity,
50% inhibitory concentration of cell growth).
Figure 2. The binding site used in our models. PDB X-ray structure
2ZD1 of RT with Rilpivirine, an NNRTI like the analog series we modeled
and shown in grey. The residues that were used to identify the binding
site (and which were used for activity modeling) are shown in black and
red. The black residues are only mutated in sequence 7 (heavy mutant)
while the red residues are mutated in more than one sequence.
Indicated by a green ribbon is the ‘A’ chain of HIV RT while the ‘B’ chain
is displayed in yellow.
doi:10.1371/journal.pone.0027518.g002
Figure 1. Graphical representation of the NNRTI dataset. (A) Our dataset consisted of 451 compounds (in rows) and 14 sequences (in
columns) of HIV Reverse Transcriptase with about 60% of the experimental data pairs known. Black indicates a low pEC50, grey indicates a high pEC50
and white indicates a missing value. (B) The dataset with the missing pEC50 values completed by our model from which 317 experimental validation
data points were chosen.
doi:10.1371/journal.pone.0027518.g001
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In order to assess the models’ capability to extrapolate between
the different sequences we performed ‘Leave-one-sequence-out
validation’ (LOSO). In this approach for each of the 14 sequences
all data points of the sequence under consideration are left out of
the training set, a model is trained on the remainder and the points
left out are used as a test set for that model. Both the RMSE and
the R0
2 values of the validation plot were subsequently determined
for each of the 14 sequences in turn.
Model interpretation
To determine the effect of individual residues, for each sequence
each residue was mutated back to wild type in silico. Subsequently
for all compounds the model prediction on the original mutant
sequence was compared with the prediction of the model on the in
silico changed mutant sequence. The difference was interpreted as
the change in pEC50 induced by that particular residue. From all
these changed prediction values the following values were
calculated: the average overall, the average per sequence and
per individual mutation. This provided the model interpretability.
However, changes that led to a 0 value shift in pEC50 were
removed in the calculation of the average per position since in all
cases this was caused by mutation back to wild type of a residue
that was already wild type in that particular sequence. In addition
the large amount of 0 value shifts lead to a shift of the average
towards 0 when it was calculated thereby masking the actual
contribution of mutations.
To interpret the influence of compound substructures a slightly
different approach was chosen. Here each FCFP_6 feature,
corresponding with a particular substructure, was substituted by
the feature representing a single Carbon atom (‘0’). Since this
carbon atom was already present in all compounds, its effect on
binding serves as a calibration. Subsequently the full model was
used to predict the pEC50 of the adapted compound fingerprint
lacking a certain substructure on all sequences and compared with
the model prediction of the original compound fingerprint on all
sequences. From all these changed predictions the average overall
and per sequence was calculated for that particular feature, or
chemical substructure in this case.
Chemistry
Synthesis of the analog series we used in this work has been
described in multiple patents. Compound 1 is listed in patent WO
2007/113256 [40], compound 2 is listed in WO 2008/080965
[41] and compounds 3 and 4 are listed in WO 2008/080964 [42].
Compound 6 is listed in patent WO 2008/080965 [41],
compounds 5, 7 and 8 are published in WO2007/113254 [43].
In addition the electronic Supporting information to this work
contain the structures of 57 of the modeled compounds. For these
compounds the full biological activity spectrum on the 14
sequences as we had it available is included along with the
pEC50 predicted by our model on each of the 14 sequences (Table
S4 and Archive S1).
Results and Discussion
In the current work PCM was applied to a data set of Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), which
constitutes one of the major classes of anti HIV drugs on the
market. Among these are compounds such as Nevirapine [44] and
Efavirenz [45], but also novel compounds such as Etravirine [46],
which was approved by the FDA as recently as 2008. Since
NNRTIs are allosteric binders they have shown considerably
fewer side effects than orthosteric drugs [47]. However they are
also known for a quick onset of viral resistance due to the
accumulation of resistance associated mutations [48,49]. Hence,
the pharmacological profile of NNRTIs is highly desirable, but
their effectiveness is hampered by the onset of resistance. This
problem is also encountered in other viral infections like Hepatitis
B [50], Hepatitis C [51] and Influenza A (H5N1) [52,53].
Resistance can therefore be considered a universal problem when
developing a new anti-viral drug. Thus, when new anti-virals are
developed it is important that they retain their effectiveness despite
the presence of these mutations. To be able to predict the activity
of a preclinical drug candidate on an adapted pathogen would be
an important contribution to drug discovery. Here we present an
application of PCM that can predict drug performance on
unknown sequences or adapted pathogens, when staying within
model limitations.
Solving the problem of sparse data sets
Our data set contains compounds that inhibit wild type Reverse
Transcriptase (RT), but also some that inhibit a number of RT
sequences that are highly resistant against inhibition. NNRTIs are
allosteric inhibitors of RT, which is illustrated in Figure 2 [33].
Incomplete bioactivity data sets are common in real-world settings,
and this study is no exception. The data set is graphically displayed
in Figure 1, with ‘blanks’ representing unknown data points that
we would like to predict using computational methods. A pEC50
value was available for approximately 60% of the data set.
In a preclinical drug discovery setting, the ability to make
decisions on a full rather than a sparse matrix increases the
likelihood that the best candidate will be selected. This is of vital
importance as a SAR table of drug – target interactions does not
necessarily show linear relationships, e.g., a substituent in a given
compound will not lead to the same increase or decrease in
binding on different targets. This is even the case in analog series
like our data set [54,55]. Especially in anti-viral research
Figure 3. Model performance in the prospective experimental
validation. Shown are both predictive performance of the model
(black dots; R0
2: 0.69, RMSE: 0.62 log units) and assay reproducibility
(grey squares; R0
2: 0.88, RMSE: 0.50 log units). The continuous lines
indicate an error of 1 log unit, while the center dashed line indicates a
perfect correlation (see main text for further details).
doi:10.1371/journal.pone.0027518.g003
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sequences. It is this behavior we are able to capture and translate
into accurate predictions.
Prospective Experimental Model Validation
During model development, learning curves were generated
that represent in silico validation, in addition we performed Y-
scrambling [56] (Figure S9 and Figure S11). More importantly, we
predicted the pEC50 of 317 unknown compound – target pairs.
These predictions were subsequently measured experimentally. By
predicting first and subsequent experimental validation, we obtain
an estimate of model performance when considering novel
compound – target pairs. Here we explicitly selected the more
‘difficult’ compound – target pairs; namely those with predicted
pEC50 values that are either atypical for the particular compound
tested (compound outliers), or for the particular sequence under
consideration (sequence outliers). It is trivial to pick the
compounds that are always active or always less active – we
precisely removed those cases from our prospective testing and
focused on the inhibitors that were predicted to be active against highly
resistant sequences, or those which were predicted to be less active against very
susceptible sequences.
Figure 3 shows the performance of the model, trained on the full
data set, in these prospective validation experiments. During cross-
validation the full model achieved a Root-Mean-Square Error
(RMSE) of 0.38 log units (with a Q
2 of 0.84) while employing 155
ligand features and 23 protein features. When applied to the new
untested data, the model achieves an RMSE of 0.62 log units and
an R0
2 of 0.69 in the prospective validation. Our model can
predict the pEC50 of untested compound – target pairs with average
accuracy of 0.62 log units. This RMSE approaches the
reproducibility of the assay which was 0.50 log units (R0
2 of 0.88).
To benchmark this performance against conventional ap-
proaches we applied QSAR modeling, k-Nearest Neighbor
(kNN) modeling (using 3, 10 or 20 nearest neighbors and based
on compound, target, or compound and target information) and
pEC50 scaling to the same data set. The results are shown in
Table 2. Here PCM outperforms QSAR and all forms of kNN
modeling, while pEC50 scaling seems to perform slightly better.
More specifically, PCM had an RMSE of 0.62 log units, while
kNN showed 0.90 for the best model and scaling performed
slightly better with 0.57. The R0
2 reached 0.69 for PCM, where
kNN showed 0.41 and scaling also reached 0.69. Scaling of pEC50
values performs second best but this method has two major
disadvantages. When we consider the sequence and compound
outliers, PCM outperformed the simple pEC50 scaling. It is
precisely those data points that points are most interesting in
research. The sequence outliers represent the inhibitors that
inhibit all present HIV mutants, candidates to select in lead selection.
The compound outliers can be completely inactive on one
particular sequence, candidates to avoid in lead selection. When
considering these compounds, the average RMSE was 0.52 for
PCM and 0.58 for scaling (R0
2 was 0.61 for PCM and 0.59 for
scaling). A second disadvantage of scaling is that this method
cannot be applied to untested viral sequences, whereas PCM can.
Hence, we conclude that the prospective experimental valida-
tion confirms the validity of our model, and the applicability of
PCM to extrapolate in both ligand (chemical) space and target
(biological) space. The other benchmarked techniques, kNN and
QSAR, do not accurately capture the compound – target
interaction space. The ability to model all these situations with a
comparable reliability and the possibility to interpret the model
from both a sequence and compound perspective, are the major
advantages of PCM over kNN, QSAR and scaling methods.
Table 2. Performance of different methods in experimental validation.
Validation
Experiment Assay PCM
pEC50
scaling QSAR
3-NN
(both)
3-NN
(target)
3-NN
(cmpd)
10-NN
(both)
10-NN
(target)
10-NN
(cmpd)
20-NN
(both)
14-NN
(target)
20-NN
(cmpd)
R0
2 (Full plot) 0.88 0.69 0.69 0.31 0.38 0.04 0.21 0.41 0.21 0.28 0.40 0.21 0.28
RMSE (Full plot) 0.50 0.62 0.57 0.96 0.90 1.55 1.24 0.90 1.29 1.16 0.90 1.21 1.17
R0
2 (Sequence Outliers) 0.88 0.65 0.52 0.32 0.32 ,0.00 ,0.00 0.32 0.15 0.03 0.32 0.22 0.02
RMSE (Sequence Outliers) 0.50 0.39 0.52 1.40 0.57 2.25 1.68 0.57 1.88 1.65 0.57 1.79 1.67
R0
2 (Compound Outliers) 0.88 0.56 0.65 0.39 0.30 0.19 0.18 0.36 0.49 0.33 0.38 0.54 0.35
RMSE (Compound Outliers) 0.50 0.65 0.64 0.72 0.87 1.18 1.05 0.86 0.90 0.93 0.86 0.82 0.92
R0
2 (Outliers) 0.88 0.61 0.59 0.36 0.31 ,0.00 0.08 0.34 0.32 0.18 0.35 0.38 0.19
RMSE (Outliers) 0.50 0.52 0.58 1.06 0.72 1.72 1.37 0.72 1.39 1.29 0.72 1.31 1.30
PCM and pEC50 scaling outperform the other techniques (QSAR and k-Nearest Neighbors) with pEC50 scaling having a slight advantage. However, PCM performs better
when the selection is narrowed to those compound – sequence pairs that show a pEC50 two standard deviations higher or lower than average (shown here as Sequence
and Compound Outliers). Also shown is the average score of each technique on the combined outliers (shown as Outliers). Negative values are denoted as ,0.00.
doi:10.1371/journal.pone.0027518.t002
Figure 4. Extension of the applicability domain to target space.
Prediction error (measured as R0
2 and RMSE in log units) versus the
average similarity of the sequence to the rest of the training set,
extending the ‘Molecular Similarity Principle’ to biological space which
is of crucial relevance in PCM. It can be seen that a higher similarity to
the training set leads to more accurate predictions. Still, predictions on
the most dissimilar sequence have an average error of less than 1 log
unit.
doi:10.1371/journal.pone.0027518.g004
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In the prospective validation we noticed that a number (15) of
data points were predicted inaccurately with an error larger than
twice the RMSE, all of which involved sequence 7. Trying to
elucidate the reason for this behavior the different sequences were
clustered based on similarity (Figure S5 for details), where
sequence 7 was found to be most dissimilar to all other sequences,
containing a rather large number of 13 point mutations (for
sequence information see Table 1). In addition, it is the sequence
with the smallest number of tested compounds in the training set,
thus diminishing the number of compound – target pairings that
were used in the model directly (without extrapolation from
neighboring sequences), thereby rationalizing the large number of
false predictions on this sequence.
In order to systematically investigate the dependence of the
prediction error on the sequence similarity we plotted the
prediction error as a function of the average Tanimoto similarity
of the individual sequences to the rest of the training set (shown in
Figure 4). A correlation between model error and average
sequence similarity is observed. The prediction error increases
when the average similarity decreases between the sequence, for
which the compound activity is predicted, and the rest of the
training set sequences. This observation is an extension to the
‘Molecular Similarity Principle’ which states that similar com-
pounds have similar properties, and in this work we are able to
show that this paradigm also holds in biological space where similar
sequences show similar ligand binding abilities; a concept we are now able
to quantify numerically. This extends recent work on ‘applicability
domains’ and ‘activity cliffs’ by also taking the biological target
side into account [54,55,57,58]. An improved distance measure is
an ensemble of both the distance between the compounds (Figure
S10), as has been previously shown [16], and the distance on the
target side. To our knowledge this neighborhood behavior in target
space has not been previously shown but is a natural extension of
the chemical similarity principle to this new technique.
The dependence of model accuracy on the average distance
provides a useful tool to set the model applicability domain. As this
distance is a property dependent on the training set on one hand
and the unknown compound – target pair on the other hand it can
be measured before any model prediction is made. Furthermore,
neighborhood behavior can determine beforehand if the model is
capable of predicting pEC50 changes on a previously untested
genotype. This approach ensures that only model predictions with
certain accuracy are used and that those that do not meet this
accuracy are disregarded. For our current model this accuracy is
defined as an error in pEC50 prediction (Figure 4) but this can also
be an error in pKi value or any other value the model is trained to
predict.
How to anticipate bioactivity for novel protein targets?
As we have shown that our model displays neighborhood
behavior in target space, here we explore the possibility to use such
a model in extrapolation. Conventionally a fraction of the full data
set is left out from the training set when testing bioactivity models.
The ability of the model to make predictions for the previously
untested (‘novel’) compounds is taken as a predictor of model
performance. In our case, we not only extrapolated in compound
space, but also in sequence space. Hence, in order to confirm the
ability of the model to extrapolate the activity of compounds to
related sequences we performed a ‘Leave-one-sequence-out’
experiment (LOSO). Here, it emulates the prediction of inhibitor
activity for a virus with a not previously encountered RT sequence,
based solely on bioactivity measurements against other sequences
in the data set. While applied to enzyme mutants here, the concept
is generally applicable and the authors are currently investigating
its performance on other target families such as GPCRs.
Figure 5 shows the R0
2 and RMSE of the LOSO validation
experiment (see Figures S1 and S2 for additional information
including error depending on similarity to the training set in
sequence space). We observe that for 13 of the 14 sequences an
RMSE of less than one log unit was obtained, and five of the 14
sequences even yielded an RMSE of less than 0.5 log units, which
is the order of magnitude of assay reproducibility. Most
interestingly, the model was able to use the information contained
in all the different mutant sequences and predict the affinity of the
compounds on the wild type sequence (Sequence 1). This means
that this LOSO-1 model was able to deconvolute the individual
contributions of the different mutants. Furthermore other LOSO
models were also capable of predicting activity on unknown
sequences 2–5 and 9–14. All these sequences contain very different
mutations (Table 1). Finally, the LOSO-7 model was able to
predict the pEC50 of the compounds on the ‘‘heavy’’ mutant
(sequence 7), which contains a total of 13 point mutations. These
findings underline the ability of PCM to extrapolate in target
Figure 5. Performance of PCM in leave-one-sequence-out experiments. Performance was measured by R0
2 and the RMSE in log units. The
number below the bar corresponds to the sequence left out of the training set.
doi:10.1371/journal.pone.0027518.g005
Proteochemometric Guided Lead Optimization
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27518space, which supports the application of the technique to predict
compound activity on different mutants.
Our results show that the model is indeed able to predict the
pEC50 values of a known compound on an unknown sequence.
However it should be noted that PCM performs lesser in 2 of the
14 mutants considered. The first of the two exceptions is sequence
6, which can be seen as a singleton since one of the mutations it
carries (E138G) is only present in this particular sequence.
Therefore, bioactivity prediction based on other sequences that
do not carry this mutation is not straightforward. It was already
known from the full model interpretation (see ‘Model Based
Interpretation of Mutants’) that the impact of this mutant was
underestimated. The LOSO-6 model correctly predicted that all
compounds have a lower activity on this sequence (giving rise to a
small RMSE value); however, the ranking among compounds is
not very accurate (explaining the low R0
2).
The second sequence where our model underperforms is
sequence 8. This case is different from the previous one: while
the model is able to correctly rank the compounds, leading to an
acceptable R0
2 of about 0.6, it consistently overpredicts the activity
of compounds, leading to a high RMSE. In sequence 8 at position
101 a positively charged lysine residue is replaced with a proline,
which likely induces conformational changes to the backbone of
the protein. K101P is present as a single mutation in sequence 8,
as well as in combination with a total of 12 other mutations in
sequence 7 (which is then the only sequence that contains K101P
in the training set when sequence 8 is left out for LOSO
validation). Hence, the model likely underestimates the impact of
the K101P mutation due to the large number of other mutations
present in sequence 7; it is not able to deconvolute the impact of
every single mutation properly. In this case, while the model would
overestimate drug activity on this particular target, in a computer-
aided compound selection setting the correct candidate would still
be identified due to the accurate ranking of the compounds by the
model.
Model performance in relation to chemical structure
To get an idea of the ability of the LOSO models’ ability to
predict individual compounds we have shown representative
examples of compounds either predicted accurately or inaccu-
rately in Figure 6. The activities of compounds 1 and 2 on the
different sequences were correctly predicted by our leave-one-
sequence-out models, while compounds 3 and 4 were predicted
inaccurate (see Figures S3 and S4 for the predictions and
experimental activities of the compounds discussed here). Please
note that we made predictions challenging as we used LOSO
models to predict the activity of compounds on the sequences left
out of the training of these exact LOSO models. It is therefore a
realistic emulation of a preclinical PCM application.
From the data we conclude that inaccurately predicted
compounds have a large functional group in the 4 position of the
pyrimidine ring. Apparently the LOSO models are unable to
capture this information correctly. When we further analyzed the
individual predictions on the different mutants (shown inFigure S4),
Figure 6. Example structures that where included in the model. A selection of both compounds containing accurately (1,2) and inaccurately
modeled chemistry (3,4). Also shown are compounds containing a substructure positively correlated with pEC50 (5,6) and compounds containing a
substructure negatively correlated with pEC50 (7,8). In the upper part, shown are sample compounds that were accurately predicted using the LOSO
models, a low RMSE (1, RMSE was 0.22 log units, R0
2 was 0.96) and a high R0
2 (2,R 0
2 was 0.89 , RMSE was 0.26). Secondly, sample compounds that
were predicted inaccurately using the LOSO models, a high RMSE (3, RMSE was 1.12 log units, R0
2 was 20.10) and a low R0
2 (4,R 0
2 was 23.66, RMSE
was 0.61). The lower part shows the 17
th best substructure (5) and the 30
th best substructure (6). Conversely the 3
rd worst substructure (7) and the
4
th worst substructure (8) are depicted.
doi:10.1371/journal.pone.0027518.g006
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log units) on the majority of the sequences. The underperformance
for compound 3 is caused by overprediction on sequence 8 (2.7 log
units, carrying K101P) and the underperformance of compound 4
by underprediction on sequence 2 (carrying V179F).
To explain this behavior, we need to consider the ligand binding
mode. A shared binding mode of all compounds is very likely since
i), they all share a common chemical scaffold and ii), NNRTIs are
known to have a highly homologous binding mode [59]. Hence we
can correlate these mispredictions with the protein structure. The
substitution position on the pyrimidine ring in the compounds
corresponds to the location of residues L100, K101 and V179 in
crystal structure 2ZD1. It is known that these residues mutate
easily and sequences carrying point mutations in this location are
present in our training set [60]. When studying the crystal
structure, it can be seen that the side chains of these residues are
likely to hamper the binding of compounds with a large functional
group in position 4.
Hence, we propose the presence of a large functional group on
position 4 on the pyrimidine ring to be a predictor of insufficient
model performance in combination with mutations on positions
101 and 179 in the protein. While compounds with a large
substituent on the 4 position are accurately predicted on targets not
carrying mutations on positions 101 and 179, they tend to be
predicted inaccurately when the targets are mutated in these
positions. However, if no large substituent is present on the 4
position, compounds are predicted accurately on targets carrying
mutations on positions 101 and 179. Using this knowledge we can
define an applicability domain when applying this particular
model, but this finding should also be taken as a warning when
using any PCM model to predict the affinity of known compounds
on unknown sequences.
Model based interpretation of mutations
After completion of the full validation, the final full model was
subsequently interpreted to explain the differences in activity of the
compounds on the individual mutants. This is the model we used
to perform the experimental validation and not one of the LOSO
models. Firstly we focused on the sequence side of the model
(Table 1 and for a multiple sequence alignment see Figure S6). By
correlating model predictions of all compounds on each mutant
sequence, where all amino acids were replaced in turn by their
wild type counterpart on that particular position, an overview of
the variation present at all individual residues was created
(Figure 7A). The full model explains the lowered activity (pEC50)
on mutants mainly by mutations at residues 100, 101, 103, 162,
179, 181, 188, 227, 234 and slightly by residue 138 on the ‘b’
chain. Interestingly the model interprets mutations at positions 89,
102, 118, 190, 203, 207, 210, 215, 219, 245 to actually slightly
increase compound activity. Residues 106, 169 and 214 have little
influence in this model and residue 211 does not seem to
contribute at all (Figure S7 shows the variation in pEC50 caused by
individual mutations).
The main contributor to lowered affinity appears to be residue
179 rather than residue 181, while the latter is known to lead to
NNRTI cross resistance [60]. Supporting this finding, it is known
that clinically used Etravirine, a compound similar to but not
included in our data set, is also sensitive to mutations at position
179 (V179D, V179F, and V179T [60]). Secondly, the influence of
mutations at position 101 differs widely indicated by the high
standard deviation. This is caused mainly by the K101P mutant,
which causes a large decrease in pEC50 for some compounds and
very little for others, depending on the chemistry (see below). The
K101E mutant overall has little influence. This interpretation is in
line with the results from the LOSO experiments mentioned above
where both residues 101 and 179 were identified as having a high
impact on model reliability.
Model based interpretation of ligand substructures
Similar to the mutation interpretation, the full model was
interpreted to elucidate the average contribution of individual
compound substructures to changes in activity (Figure 7B). Here
the substructure that was being investigated was replaced by a
single carbon atom in all compounds and the subsequent model
predictions were compared to the model predictions for the
original compounds. Figure 7B shows the contribution of the
substructures after a selection was made to only use substructures
that occur in more than one compound in order to lower a bias of
a continuously active compound (resulting in 1068 of 2546
substructures). In the figure some examples of substructures that
Figure 7. Interpretation of the full model. (A) Overview of the contribution of mutations present at all individual residue positions. The full
model explains the lowered activity (pEC50 in log units) on mutants mainly by mutations at residues 100, 101, 103, 162, 179, 181, 188, 227, 234 and
residue 138 on the ‘b’ chain. (B) Overview of the contribution of the different chemical substructures. Substructures occurring only in a single
compound have been removed and the remaining substructures have been numbered sequentially. Several substructures have been visualized and
linked to their position on the overview.
doi:10.1371/journal.pone.0027518.g007
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Sequence Compound with highest pEC50 Activity (pEC50) Full Model (pEC50)
Difference (Activity and
Model)
All 326 8.39 (60.61) 8.53 (60.73) 0.14
1 365 9.16 9.55 0.39
2 221 8.19 8.38 0.19
3 79 8.71 8.81 0.10
4 321 8.83 8.79 0.04
5 321 9.12 8.73 0.39
6 221 8.01 7.93 0.08
7 364 untested 7.50 n/a
8 221 untested 8.42 n/a
9 365 untested 9.43 n/a
10 326 untested 9.23 n/a
11 151 9.05 8.86 0.19
12 321 untested 9.29 n/a
13 100 9.06 8.87 0.19
14 79 9.51 9.62 0.11
Average 0.18
Overview of the compounds with the highest pEC50 as obtained from the model. Shown are the pEC50 values differentiated over all sequences (all) or per sequence.
Also shown is the standard deviation of the distribution over all sequences used to calculate this mean value. It should be noted that compound 326 was not tested on
sequences 9, 10 and 14, illustrating the importance of extrapolating in bioactivity space.
doi:10.1371/journal.pone.0027518.t003
Table 4. Worst performing compounds (per sequence and overall).
Sequence Compound with Lowest pEC50 Activity (pEC50) Full Model (pEC50)
Difference (Activity and
Model)
All 109 5.85 (60.54) 5.82 (60.66) 0.03
1 248 6.09 6.01 0.08
2 109 untested 4.87 n/a
3 422 untested 5.78 n/a
4 84 5.84 5.67 0.17
5 84 5.65 5.54 0.11
6 109 4.60 4.06 0.54
7 439 5.01 5.20 0.19
8 84 4.74 5.20 0.46
9 248 untested 5.96 n/a
10 181 5.82 6.01 0.19
11 181 5.42 5.61 0.19
12 109 5.90 6.09 0.19
13 181 5.11 5.29 0.18
14 181 5.62 5.81 0.19
Average 0.21
Overview of the compounds with the lowest pEC50 as obtained from the model. Shown are the pEC50 values differentiated over all sequences (all) or per sequence. Also
shown is the standard deviation of the distribution over all sequences used to calculate this mean value. It should be noted that compound 109 was not tested on
sequences 2, 7 and 8, illustrating the importance of extrapolating in bioactivity space.
doi:10.1371/journal.pone.0027518.t004
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shown. For a full table with the top 15 best and top 15 worst
substructures, please see Table S1 and Table S2. Figure 6
(compounds 5,6) shows two examples of compounds that contain
a substructure, which has been highlighted, that the model
predicts to lead to a good activity and two examples of compounds
(7,8) that contain a substructure that the model predicts to have a
negative effect on activity. The effect is expressed as an average
increase or decrease of all compounds containing that substructure
and their activities on all sequences. Compound 5 contains the
17
th best substructure, leading to an average increase in pEC50 of
0.14, and compound 6 contains the 30
th best substructure, leading
to an average increase in pEC50 of 0.12. Therefore these
substructures constitute chemistry that is optimally contained in
the compound. Compound 7 contains the 3
rd worst substructure,
leading to an average decrease in pEC50 of 0.23, and compound 8
contains the 4
th worst substructure, leading to average decrease in
pEC50 of 0.19. These two substructures constitute chemistry that is
rather avoided in possible drug candidates.
Application of PCM in preclinical drug research
Wehave shown that PCM can be applied in a preclinical setting to
predict the resistance profile of compounds. In addition we can
interpret our final full model and identify favorable and unfavorable
substructures, providing insights that can be used in compound
design. For this data set we can conclude that the mutations in the
protein sequences have a larger impact on pEC50 values than the
compound substructures. However, we have also shown that the
substructures still possess a significant influence, as PCM was the only
technique that was able to combine target and substructures
information.
Combining all our results from prospective experimental
validation, the LOSO and the model interpretation, we feel
confident that our model can be used to estimate the activity of
previously untested compound – sequence pairs, with the main
limitation (which can be quantified) being the similarity of the target
protein. This opens the door for models that are able to predict the
changes in activity of different compounds on clinical isolates
obtained from patients [13]. PCM can thereby serve as a modeling
tool to predict the activity for untested compound – isolate pairs
before any assay measurement is performed, providing a quick
guidance to medicinal chemists in the development of drugs based
on their expected resistance profile. An example of this application
is given in Tables 3 and 4, listing which inhibitors show best activity
against a particular sequence and for which inhibitors resistance
would be expected. (Table S4lists a total of 57 compounds and their
activity on the 14 sequences) Likewise, our method also aids in the
development of drugs that have a broad inhibition profile.
Noteworthy is that eight of the 28 specific compound - sequence
predictions are untested compound – sequence pairs, which
underlines the value of PCM to extrapolate to untested drug –
sequence pairings, a feature not possible to achieve in conventional
(single-target based) bioactivity modeling.
Conclusions
In this work we have shown how to incorporate personalized data
(specific viral mutants) as a tool to select optimal candidates in drug
development by using proteochemometrics modeling in combination
with a large scale experimental validation of inhibitors of HIV
Reverse Transcriptase. While applied here to NNRTIs, PCM is a
universally applicable method since all it requires is the sequence of a
target of interest and structures of ligands.Thesetwo prerequisites are
something that is available in any preclinical drug research project.
We employed a prospective validation of 317 new experimental data
points and a new type of ‘leave one sequence out’ validation
(representing the case of a previously untested virus genotype). We
were able to predict which compounds are best for a particular HIV
RT sequence (with high accuracy in 12 out of the 14 sequences in the
data set). We established that distance in biological (target) space is
tightly correlated with prediction performance, enabling us to judge
where the model likely succeeds, and where it may fail. Hence, in this
work, we present a real-world scenario of HIV drug development,
make practical steps towards drug design tailored towards specific
patients, and we aim to extend this to other target families in the
future.
Supporting Information
Additional figures (Figures S1, S2, S3, S4, S5, S6, S7, S8, S9,
S10, S11), four tables (Tables S1, S2, S3, S4), the final model and
57 of the here modeled compounds with biological activity ( are
available online. A protocol to be run in pipeline pilot to apply this
model and perform PCM is also available online.
Supporting Information
Figure S1 Correlation parameters plotted against the
average similarity with the training set. (A) The R0
2 of the
different leave-one-sequence-out experiments (LOSO) against the
average similarity between that specific sequence and the training
set. (B) The RMSE of the different leave-one-sequence-out
experiments against the average similarity between that specific
sequence and the training set.
(TIF)
Figure S2 The distribution of the correlation parame-
ters when validating individual compound predictions
using the individual LOSO models. (A) Distribution of the
RMSE and the R0
2 of the individual compound predictions using
theLOSOmodels.Thecompoundshavebeenrankedbyincreasing
RMSE in (A), the corresponding R0
2 is shown in (B). Please note
that the number on the x-axis is not the name of the compound, it is
merely a serial number. Likewise the compounds have been ranked
by increasing R0
2 (C) the corresponding RMSE is shown in (D).
(TIF)
Figure S3 Two compounds that were predicted accu-
rately using the LOSO models. (A) Prediction of the activity
(pEC50 value) of compound 1 on the different sequences using the
LOSO models (RMSE of 0.22 log units, R0
2 of 0.96). (B)
Prediction of the activity (pEC50 value) of compound 2 on the
different sequences using the LOSO models (RMSE of 0.26 log
units, R0
2 of 0.89).
(TIF)
Figure S4 Two compounds that were predicted inaccu-
rately using the LOSO models. (A) Prediction of the activity
(pEC50 value) of compound 3 on the different sequences using the
LOSO models (RMSE of 1.12 log units, R0
2 of 20.10). (B)
Prediction of the activity (pEC50 value) of compound 4 on the
different sequences using the LOSO models (RMSE of 0.61 log
units, R0
2 of 23.66).
(TIF)
Figure S5 Sequences present in the dataset clustered to
similarity based on the protein descriptor.
(TIF)
Figure S6 Multiple sequence alignment of the used
mutants. Outside the shown alignment the 14 sequences were
equal; therefore these residues were omitted from the PCM model.
(TIF)
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the full model of all present mutants. The standard
deviation was determined over all calculated pEC50 changes.
(TIF)
Figure S8 Overview of the pEC50 values of all compound
– sequence pairs.
(TIF)
Figure S9 PCM and QSAR learning curves. As training is
performed on an increasing part of the data set, validation is
performed on a decreasing part of the data set. The PCM models
are shown by solid lines and the QSAR by dashed lines. The
validation parameters were calculated per sequence, using a single
PCM model for all sequences, as well as for comparison and
dedicated QSAR models for each individual sequence. The error
bars indicate the standard deviation over the R0
2 and RMSE
values of the validation on the different sequences. The PCM
single models outperform the dedicated QSAR models in each
case both measured by the R0
2 and the RMSE.
(TIF)
Figure S10 The maximal distance of the compound
from the training set plotted to the prediction error. The
plot shows that the distance relates to the prediction error as
compounds closer than 0.98 are predicted better than compounds
further away than 0.98 from the training set.
(TIF)
Figure S11 Y-scrambling plot. In order to rule out chance
correlations 100-fold Y-scrambling was performed. After scram-
bling the pEC50 values, these 100 data sets were in each case
divided into a training set consisting of 80% of the total set and a
test set consisting of 20%. The models built on permutated data
cannot be validated with a Q
2,R
2 and R0
2 of approximately 0.
After training and validation, Q
2,R
2 of the training and R0
2 of the
validation were plotted against the similarity of the scrambled
dataset with the original training set. This correlation was defined
as the % of compounds that had a pEC50 value within 0.3 log units
of its true value. A simple linear regression was subsequently
performed for Q
2,R
2 and R0
2. The regression lines for Q
2,R
2 of
the training and R0
2 of the validation crossed the y-axis at 20.12,
20.10 and 20.16 respectively. We conclude that it is highly
unlikely that our model was created based on chance correlations
between the different descriptors. Therefore we are modeling an
actual correlation between the pEC50 values on the one hand and
the compounds and proteins on the other hand.
(TIF)
Table S1 The top 15 substructures contributing the
most to binding on all sequences. Mean indicates the mean
increase in pEC50 by the presence of that particular substructure,
StdDev represents the standard deviation of the distribution of all
changes in pEC50 correlated with the presence of that substructure
and N represents the amount of predicted changes within this
distribution. Binvalue is the identifier for that particular substruc-
ture (FCFP_6 format) and the properties Variance, Skew and
Kurtosis have also been calculated over the distribution to
determine the distribution pattern of the changes caused by that
substructure.
(DOC)
Table S2 The top 15 substructures leading on average
to a lower pEC50 on all sequences. Mean indicates the mean
decrease in pEC50 by the presence of that particular substructure,
StdDev represents the standard deviation of the distribution of all
changes in pEC50 correlated with the presence of that substructure
and N represents the amount of predicted changes within this
distribution. Binvalue is the identifier for that particular substruc-
ture (FCFP_6 format) and the properties Variance, Skew and
Kurtosis have also been calculated over the distribution to
determine the distribution pattern of the changes caused by that
substructure.
(DOC)
Table S3 All AAindices used with their reference on the
AAindex website. This table lists all indices we used to create a
unique hashed value per amino acid.
(DOC)
Table S4 The complete SAR of 57 of the modeled
compounds.
(DOC)
Archive S1 Model and sample data set.
(RAR)
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